NASDAQ:HTGM - HTG Molecular Diagnostics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$3.60 +0.05 (+1.41 %)
(As of 05/24/2018 04:00 PM ET)
Previous Close$3.60
Today's Range$3.52 - $3.62
52-Week Range$1.59 - $5.83
Volume325,026 shs
Average Volume1.55 million shs
Market Capitalization$102.42 million
P/E Ratio-2.01
Dividend YieldN/A
Beta1.61

About HTG Molecular Diagnostics (NASDAQ:HTGM)

HTG Molecular Diagnostics logoHTG Molecular Diagnostics, Inc. develops and markets products and services based on proprietary technology that facilitates the routine use of targeted molecular profiling. The company's products, HTG Edge and HTG EdgeSeq platforms include instrumentation (or platforms), consumables comprising assay kits, and software analytics that automate sample processing and profiles various molecular targets from samples a fraction of the size required by prevailing technologies. Its platforms generate a molecular profiling library for detection using next-generation sequencing. The company's assay product offerings include HTG EdgeSeq oncology biomarker panel; HTG EdgeSeq immuno-oncology assay; HTG EdgeSeq lymphoma panel; HTG EdgeSeq microRNA whole-transcriptome assay; and HTG EdgeSeq DLBCL cell of origin assay. It also provides sample processing and molecular profiling of retrospective cohorts through its VERI/O laboratory; and designs custom panels for biopharmaceutical customers and research services, resulting from research and development collaboration agreements with biopharmaceutical customers. It serves biopharmaceutical companies, academic research centers, and molecular testing laboratories. The company has a research collaboration with Insituto Valenciano de Oncologia on breast cancer recurrence risk. HTG Molecular Diagnostics, Inc. distributes its instruments and consumables directly in the United States and Europe; and through distributors in parts of Europe and internationally. The company was formerly known as HTG, Inc. and changed its name to HTG Molecular Diagnostics, Inc. in March 2011. HTG Molecular Diagnostics, Inc. was incorporated in 1997 and is based in Tucson, Arizona.

Receive HTGM News and Ratings via Email

Sign-up to receive the latest news and ratings for HTGM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Analytical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:HTGM
CUSIPN/A
Phone877-289-2615

Debt

Debt-to-Equity Ratio0.31
Current Ratio9.80
Quick Ratio9.59

Price-To-Earnings

Trailing P/E Ratio-2.01
Forward P/E Ratio-5.45
P/E GrowthN/A

Sales & Book Value

Annual Sales$14.76 million
Price / Sales6.92
Cash FlowN/A
Price / CashN/A
Book Value$1.09 per share
Price / Book3.30

Profitability

EPS (Most Recent Fiscal Year)($1.79)
Net Income$-18,960,000.00
Net Margins-105.56%
Return on Equity-338.96%
Return on Assets-66.49%

Miscellaneous

Employees98
Outstanding Shares28,370,000

HTG Molecular Diagnostics (NASDAQ:HTGM) Frequently Asked Questions

What is HTG Molecular Diagnostics' stock symbol?

HTG Molecular Diagnostics trades on the NASDAQ under the ticker symbol "HTGM."

How were HTG Molecular Diagnostics' earnings last quarter?

HTG Molecular Diagnostics (NASDAQ:HTGM) posted its quarterly earnings data on Thursday, May, 10th. The medical research company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.26) by $0.04. The medical research company earned $4.16 million during the quarter, compared to the consensus estimate of $5.24 million. HTG Molecular Diagnostics had a negative net margin of 105.56% and a negative return on equity of 338.96%. View HTG Molecular Diagnostics' Earnings History.

What price target have analysts set for HTGM?

2 brokers have issued twelve-month price objectives for HTG Molecular Diagnostics' stock. Their predictions range from $7.00 to $7.00. On average, they expect HTG Molecular Diagnostics' share price to reach $7.00 in the next twelve months. View Analyst Ratings for HTG Molecular Diagnostics.

Who are some of HTG Molecular Diagnostics' key competitors?

Who are HTG Molecular Diagnostics' key executives?

HTG Molecular Diagnostics' management team includes the folowing people:
  • Mr. Timothy B. Johnson, CEO & Director (Age 57)
  • Mr. John L. Lubniewski, Pres & COO (Age 54)
  • Dr. Patrick C. Roche Ph.D., Sr. VP of Research & Product Devel. (Age 65)
  • Mr. Shaun D. McMeans, VP of Fin. & Admin, Treasurer & CFO (Age 56)
  • Dr. Debra A. Gordon Ph.D., J.D., VP, Chief Legal Counsel & Sec. (Age 58)

When did HTG Molecular Diagnostics IPO?

(HTGM) raised $50 million in an initial public offering on Wednesday, May 6th 2015. The company issued 3,600,000 shares at $13.00-$15.00 per share. Leerink Partners served as the underwriter for the IPO and Canaccord Genuity and JMP Securities were co-managers.

Has HTG Molecular Diagnostics been receiving favorable news coverage?

News stories about HTGM stock have been trending positive recently, Accern Sentiment Analysis reports. The research group ranks the sentiment of media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. HTG Molecular Diagnostics earned a news sentiment score of 0.29 on Accern's scale. They also gave news articles about the medical research company an impact score of 47.04 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.

Who are HTG Molecular Diagnostics' major shareholders?

HTG Molecular Diagnostics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Stifel Financial Corp (0.33%), Northern Trust Corp (0.18%) and New York State Common Retirement Fund (0.17%). Company insiders that own HTG Molecular Diagnostics stock include Holdings A/S Novo, Plc Glaxosmithkline and Shaun D Mcmeans. View Institutional Ownership Trends for HTG Molecular Diagnostics.

Which major investors are buying HTG Molecular Diagnostics stock?

HTGM stock was bought by a variety of institutional investors in the last quarter, including Stifel Financial Corp, Northern Trust Corp and New York State Common Retirement Fund. View Insider Buying and Selling for HTG Molecular Diagnostics.

How do I buy shares of HTG Molecular Diagnostics?

Shares of HTGM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is HTG Molecular Diagnostics' stock price today?

One share of HTGM stock can currently be purchased for approximately $3.60.

How big of a company is HTG Molecular Diagnostics?

HTG Molecular Diagnostics has a market capitalization of $102.42 million and generates $14.76 million in revenue each year. The medical research company earns $-18,960,000.00 in net income (profit) each year or ($1.79) on an earnings per share basis. HTG Molecular Diagnostics employs 98 workers across the globe.

How can I contact HTG Molecular Diagnostics?

HTG Molecular Diagnostics' mailing address is 3430 E. GLOBAL LOOP, TUCSON AZ, 85706. The medical research company can be reached via phone at 877-289-2615.


MarketBeat Community Rating for HTG Molecular Diagnostics (HTGM)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  159 (Vote Outperform)
Underperform Votes:  140 (Vote Underperform)
Total Votes:  299
MarketBeat's community ratings are surveys of what our community members think about HTG Molecular Diagnostics and other stocks. Vote "Outperform" if you believe HTGM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HTGM will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

HTG Molecular Diagnostics (NASDAQ:HTGM) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
2 Wall Street analysts have issued ratings and price targets for HTG Molecular Diagnostics in the last 12 months. Their average twelve-month price target is $7.00, suggesting that the stock has a possible upside of 94.44%. The high price target for HTGM is $7.00 and the low price target for HTGM is $7.00. There are currently 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.002.672.67
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $7.00$6.6667$5.6667$6.1667
Price Target Upside: 94.44% upside83.15% upside58.73% upside175.30% upside

HTG Molecular Diagnostics (NASDAQ:HTGM) Consensus Price Target History

Price Target History for HTG Molecular Diagnostics (NASDAQ:HTGM)

HTG Molecular Diagnostics (NASDAQ:HTGM) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/22/2018HC WainwrightSet Price TargetBuy$7.00HighView Rating Details
3/23/2018Canaccord GenuityBoost Price TargetBuy ➝ Buy$5.00 ➝ $7.00HighView Rating Details
5/16/2017Rodman & RenshawBoost Price TargetBuy ➝ Buy$4.50 ➝ $6.00HighView Rating Details
(Data available from 5/24/2016 forward)

Earnings

HTG Molecular Diagnostics (NASDAQ:HTGM) Earnings History and Estimates Chart

Earnings by Quarter for HTG Molecular Diagnostics (NASDAQ:HTGM)

HTG Molecular Diagnostics (NASDAQ:HTGM) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.66 EPS
Next Year EPS Consensus Estimate: $-0.48 EPS

HTG Molecular Diagnostics (NASDAQ HTGM) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2018Q1 2018($0.2550)($0.22)$5.24 million$4.16 millionViewN/AView Earnings Details
3/22/2018Q4 2017($0.30)($0.15)$7.05 million$7.90 millionViewListenView Earnings Details
11/7/2017Q3 2017($0.49)($0.46)$3.20 million$3.72 millionViewN/AView Earnings Details
8/8/2017Q2($0.60)($0.60)$1.80 million$1.76 millionViewListenView Earnings Details
5/15/2017Q1($0.58)($0.73)$2.44 million$1.37 millionViewN/AView Earnings Details
3/23/2017Q4 2016($0.79)($0.76)$2.22 million$1.46 millionViewN/AView Earnings Details
11/14/2016Q3 2016($0.87)($0.92)$2.05 million$0.91 millionViewListenView Earnings Details
8/9/2016Q2($0.95)($0.98)$1.90 millionViewListenView Earnings Details
5/12/2016Q1($0.83)($1.02)$1.23 million$0.87 millionViewListenView Earnings Details
3/24/2016Q4($0.79)($0.83)$1.31 million$1.22 millionViewListenView Earnings Details
11/12/2015Q315($0.85)($0.76)$1.07 million$1.00 millionViewListenView Earnings Details
8/6/2015Q215($0.71)($1.73)$1.01 million$0.79 millionViewListenView Earnings Details
6/1/2015Q115($14.99)$1.00 millionViewListenView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

HTG Molecular Diagnostics (NASDAQ:HTGM) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

HTG Molecular Diagnostics (NASDAQ HTGM) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 7.60%
Institutional Ownership Percentage: 38.75%
Insider Trading History for HTG Molecular Diagnostics (NASDAQ:HTGM)
Institutional Ownership by Quarter for HTG Molecular Diagnostics (NASDAQ:HTGM)

HTG Molecular Diagnostics (NASDAQ HTGM) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/1/2017Shaun D McmeansVPSell945$2.11$1,993.95View SEC Filing  
11/1/2017Shaun D McmeansCFOSell945$2.26$2,135.7043,248View SEC Filing  
10/16/2017Shaun D McmeansVPSell946$2.27$2,147.4244,193View SEC Filing  
8/25/2017Holdings A/S NovoMajor ShareholderSell1,149,813$1.81$2,081,161.53View SEC Filing  
8/24/2017Holdings A/S NovoMajor ShareholderSell382,437$1.91$730,454.67View SEC Filing  
8/23/2017Holdings A/S NovoMajor ShareholderSell47,162$2.02$95,267.24View SEC Filing  
8/22/2017Holdings A/S NovoMajor ShareholderSell80,586$2.07$166,813.021,225,085View SEC Filing  
3/27/2017Plc GlaxosmithklineInsiderSell300,000$10.15$3,045,000.00View SEC Filing  
4/4/2016Debra A GordonVPSell1,672$2.89$4,832.0817,705View SEC Filing  
4/4/2016John L LubniewskiInsiderSell796$2.89$2,300.4425,114View SEC Filing  
4/4/2016Shaun D McmeansCFOSell1,601$2.89$4,626.8920,151View SEC Filing  
4/4/2016Tim B JohnsonCEOSell4,914$2.89$14,201.4651,309View SEC Filing  
3/14/2016Debra A GordonVPSell5,535$2.38$13,173.3023,518View SEC Filing  
3/14/2016John L LubniewskiInsiderSell6,889$2.38$16,395.8231,200View SEC Filing  
3/14/2016Patrick C RocheSVPSell5,929$2.38$14,111.0223,783View SEC Filing  
3/14/2016Shaun D McmeansCFOSell5,651$2.38$13,449.3825,991View SEC Filing  
3/14/2016Tim B JohnsonCEOSell10,621$2.38$25,277.9863,964View SEC Filing  
3/9/2016Debra A GordonVPSell3,256$2.69$8,758.6424,729View SEC Filing  
3/9/2016John L LubniewskiInsiderSell4,067$2.69$10,940.2332,712View SEC Filing  
3/9/2016Patrick C RocheSVPSell3,491$2.69$9,390.7925,081View SEC Filing  
3/9/2016Shaun D McmeansCFOSell3,325$2.69$8,944.2527,228View SEC Filing  
3/9/2016Tim B JohnsonCEOSell6,299$2.69$16,944.3166,306View SEC Filing  
8/24/2015Debra A GordonVPBuy1,000$5.16$5,160.001,356View SEC Filing  
8/18/2015Patrick C. RocheSVPBuy6,500$5.76$37,440.006,500View SEC Filing  
8/11/2015John L LubniewskiInsiderBuy5,000$7.67$38,350.00View SEC Filing  
5/11/2015A/S NovoMajor ShareholderBuy365,106$14.00$5,111,484.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

HTG Molecular Diagnostics (NASDAQ HTGM) News Headlines

Source:
DateHeadline
HTG Molecular Diagnostics (HTGM) PT Set at $7.00 by HC WainwrightHTG Molecular Diagnostics (HTGM) PT Set at $7.00 by HC Wainwright
www.americanbankingnews.com - May 22 at 9:45 AM
Head-To-Head Comparison: Integra Lifesciences (IART) versus HTG Molecular Diagnostics (HTGM)Head-To-Head Comparison: Integra Lifesciences (IART) versus HTG Molecular Diagnostics (HTGM)
www.americanbankingnews.com - May 21 at 5:35 AM
HTG Molecular Diagnostics (HTGM) Given a $7.00 Price Target by HC Wainwright AnalystsHTG Molecular Diagnostics (HTGM) Given a $7.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - May 15 at 1:31 PM
HTG Molecular Diagnostics (HTGM) Announces Quarterly  Earnings ResultsHTG Molecular Diagnostics (HTGM) Announces Quarterly Earnings Results
www.americanbankingnews.com - May 11 at 4:54 PM
HTG Molecular Diagnostics (HTGM) CEO T. J. Johnson on Q1 2018 Results - Earnings Call TranscriptHTG Molecular Diagnostics' (HTGM) CEO T. J. Johnson on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 11 at 8:28 AM
HTG Molecular Diagnostics (HTGM) Reports Q1 Loss of $0.22/ShareHTG Molecular Diagnostics (HTGM) Reports Q1 Loss of $0.22/Share
www.streetinsider.com - May 10 at 5:56 PM
Does HTG Molecular Diagnostics Inc’s (NASDAQ:HTGM) Latest Financial Perfomance Look Strong?Does HTG Molecular Diagnostics Inc’s (NASDAQ:HTGM) Latest Financial Perfomance Look Strong?
finance.yahoo.com - May 10 at 5:56 PM
HTG Molecular Diagnostics Reports First Quarter 2018 ResultsHTG Molecular Diagnostics Reports First Quarter 2018 Results
finance.yahoo.com - May 10 at 5:56 PM
HTG Molecular Diagnostics to Feature Its HTG EdgeSeq Precision Immuno-Oncology Panel at Booth #4113 at the American Society of Clinical Oncology (ASCO) Conference in June 2018HTG Molecular Diagnostics to Feature Its HTG EdgeSeq Precision Immuno-Oncology Panel at Booth #4113 at the American Society of Clinical Oncology (ASCO) Conference in June 2018
finance.yahoo.com - May 10 at 8:25 AM
Critical Review: HTG Molecular Diagnostics (HTGM) vs. Its CompetitorsCritical Review: HTG Molecular Diagnostics (HTGM) vs. Its Competitors
www.americanbankingnews.com - May 9 at 3:29 PM
HTG Molecular Diagnostics (HTGM) & Its Rivals Financial ContrastHTG Molecular Diagnostics (HTGM) & Its Rivals Financial Contrast
www.americanbankingnews.com - May 9 at 11:57 AM
Analyzing HTG Molecular Diagnostics (HTGM) & Its RivalsAnalyzing HTG Molecular Diagnostics (HTGM) & Its Rivals
www.americanbankingnews.com - May 9 at 1:06 AM
Financial Comparison: HTG Molecular Diagnostics (HTGM) vs. Its RivalsFinancial Comparison: HTG Molecular Diagnostics (HTGM) vs. Its Rivals
www.americanbankingnews.com - May 8 at 3:19 PM
Financial Survey: HTG Molecular Diagnostics (HTGM) versus Its RivalsFinancial Survey: HTG Molecular Diagnostics (HTGM) versus Its Rivals
www.americanbankingnews.com - May 8 at 1:30 PM
HTG Molecular Diagnostics (HTGM) & Its Competitors Critical AnalysisHTG Molecular Diagnostics (HTGM) & Its Competitors Critical Analysis
www.americanbankingnews.com - May 7 at 9:16 PM
Head to Head Comparison: HTG Molecular Diagnostics (HTGM) and Its PeersHead to Head Comparison: HTG Molecular Diagnostics (HTGM) and Its Peers
www.americanbankingnews.com - May 7 at 1:47 PM
Contrasting HTG Molecular Diagnostics (HTGM) and Its CompetitorsContrasting HTG Molecular Diagnostics (HTGM) and Its Competitors
www.americanbankingnews.com - May 7 at 10:18 AM
HTG Molecular Diagnostics and Firalis Announce an Agreement Enabling Firalis’ Commercialization of Theranostic and Research Products and Services Based on HTG EdgeSeq TechnologyHTG Molecular Diagnostics and Firalis Announce an Agreement Enabling Firalis’ Commercialization of Theranostic and Research Products and Services Based on HTG EdgeSeq Technology
finance.yahoo.com - May 7 at 8:20 AM
HTG Molecular Diagnostics (HTGM) and Its Rivals Financial SurveyHTG Molecular Diagnostics (HTGM) and Its Rivals Financial Survey
www.americanbankingnews.com - May 7 at 3:30 AM
HTG Molecular Diagnostics (HTGM) Set to Announce Quarterly Earnings on MondayHTG Molecular Diagnostics (HTGM) Set to Announce Quarterly Earnings on Monday
www.americanbankingnews.com - May 7 at 3:28 AM
HTG Molecular Diagnostics (HTGM) vs. Its Peers Critical SurveyHTG Molecular Diagnostics (HTGM) vs. Its Peers Critical Survey
www.americanbankingnews.com - May 6 at 8:16 PM
Head to Head Contrast: HTG Molecular Diagnostics (HTGM) versus Its RivalsHead to Head Contrast: HTG Molecular Diagnostics (HTGM) versus Its Rivals
www.americanbankingnews.com - May 6 at 3:19 PM
HTG Molecular Diagnostics (HTGM) Upgraded to Hold by Zacks Investment ResearchHTG Molecular Diagnostics (HTGM) Upgraded to Hold by Zacks Investment Research
www.americanbankingnews.com - May 5 at 6:37 AM
Financial Review: HTG Molecular Diagnostics (HTGM) and Its CompetitorsFinancial Review: HTG Molecular Diagnostics (HTGM) and Its Competitors
www.americanbankingnews.com - May 4 at 11:07 PM
Next Generation Sequencing (NGS) Market Analysis & Forecasts 2016-2022 by Product Type, Application, Method and ...Next Generation Sequencing (NGS) Market Analysis & Forecasts 2016-2022 by Product Type, Application, Method and ...
www.businesswire.com - May 4 at 5:33 PM
Head-To-Head Comparison: HTG Molecular Diagnostics (HTGM) vs. The CompetitionHead-To-Head Comparison: HTG Molecular Diagnostics (HTGM) vs. The Competition
www.americanbankingnews.com - May 4 at 3:29 PM
HTG Molecular Diagnostics (HTGM) Rating Increased to Hold at ValuEngineHTG Molecular Diagnostics (HTGM) Rating Increased to Hold at ValuEngine
www.americanbankingnews.com - May 4 at 12:41 AM
Reviewing HTG Molecular Diagnostics (HTGM) and The CompetitionReviewing HTG Molecular Diagnostics (HTGM) and The Competition
www.americanbankingnews.com - May 3 at 3:00 PM
Comparing HTG Molecular Diagnostics (HTGM) and pSivida (EYPT)Comparing HTG Molecular Diagnostics (HTGM) and pSivida (EYPT)
www.americanbankingnews.com - May 2 at 11:19 PM
HTG Molecular Diagnostics (HTGM) and The Competition Critical AnalysisHTG Molecular Diagnostics (HTGM) and The Competition Critical Analysis
www.americanbankingnews.com - May 2 at 3:23 PM
Financial Survey: HTG Molecular Diagnostics (HTGM) versus Its PeersFinancial Survey: HTG Molecular Diagnostics (HTGM) versus Its Peers
www.americanbankingnews.com - May 2 at 3:20 AM
Head to Head Analysis: HTG Molecular Diagnostics (HTGM) and Its CompetitorsHead to Head Analysis: HTG Molecular Diagnostics (HTGM) and Its Competitors
www.americanbankingnews.com - April 28 at 1:26 PM
Contrasting HTG Molecular Diagnostics (HTGM) & Its PeersContrasting HTG Molecular Diagnostics (HTGM) & Its Peers
www.americanbankingnews.com - April 28 at 5:20 AM
Head-To-Head Review: HTG Molecular Diagnostics (HTGM) vs. Its PeersHead-To-Head Review: HTG Molecular Diagnostics (HTGM) vs. Its Peers
www.americanbankingnews.com - April 26 at 11:14 PM
Critical Review: HTG Molecular Diagnostics (HTGM) and Its RivalsCritical Review: HTG Molecular Diagnostics (HTGM) and Its Rivals
www.americanbankingnews.com - April 26 at 1:28 PM
2 Attractive Biotechs Under $52 Attractive Biotechs Under $5
seekingalpha.com - April 24 at 5:35 PM
Financial Comparison: HTG Molecular Diagnostics (HTGM) versus Its RivalsFinancial Comparison: HTG Molecular Diagnostics (HTGM) versus Its Rivals
www.americanbankingnews.com - April 24 at 1:18 AM
Comparing HTG Molecular Diagnostics (HTGM) and Its PeersComparing HTG Molecular Diagnostics (HTGM) and Its Peers
www.americanbankingnews.com - April 20 at 9:22 PM
Analyzing HTG Molecular Diagnostics (HTGM) and Its CompetitorsAnalyzing HTG Molecular Diagnostics (HTGM) and Its Competitors
www.americanbankingnews.com - April 20 at 3:13 AM
HTG Molecular Diagnostics (HTGM) Stock Rating Upgraded by ValuEngineHTG Molecular Diagnostics (HTGM) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - April 17 at 10:55 PM
HTG Molecular Diagnostics (HTGM) Upgraded by Zacks Investment Research to "Hold"HTG Molecular Diagnostics (HTGM) Upgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - April 17 at 4:47 PM
HTG Molecular Diagnostics (HTGM) Announces Promotion of John Lubniewski to President & COOHTG Molecular Diagnostics (HTGM) Announces Promotion of John Lubniewski to President & COO
www.streetinsider.com - April 16 at 5:24 PM
HTG Promotes John Lubniewski to President and Chief Operating OfficerHTG Promotes John Lubniewski to President and Chief Operating Officer
finance.yahoo.com - April 16 at 5:24 PM
Comparing HTG Molecular Diagnostics (HTGM) & The CompetitionComparing HTG Molecular Diagnostics (HTGM) & The Competition
www.americanbankingnews.com - April 13 at 3:24 PM
HTG Molecular Diagnostics (HTGM) Given a $6.00 Price Target by HC Wainwright AnalystsHTG Molecular Diagnostics (HTGM) Given a $6.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - April 11 at 11:52 PM
HTG Molecular Diagnostics (HTGM) vs. Its Peers Financial AnalysisHTG Molecular Diagnostics (HTGM) vs. Its Peers Financial Analysis
www.americanbankingnews.com - April 11 at 5:31 AM
Comparing HTG Molecular Diagnostics (HTGM) & Its CompetitorsComparing HTG Molecular Diagnostics (HTGM) & Its Competitors
www.americanbankingnews.com - April 11 at 3:17 AM
HTG Molecular Diagnostics (HTGM) Cut to "Sell" at Zacks Investment ResearchHTG Molecular Diagnostics (HTGM) Cut to "Sell" at Zacks Investment Research
www.americanbankingnews.com - April 10 at 1:42 PM
Head-To-Head Survey: HTG Molecular Diagnostics (HTGM) & Its PeersHead-To-Head Survey: HTG Molecular Diagnostics (HTGM) & Its Peers
www.americanbankingnews.com - April 10 at 1:30 AM
ValuEngine Lowers HTG Molecular Diagnostics (HTGM) to Strong SellValuEngine Lowers HTG Molecular Diagnostics (HTGM) to Strong Sell
www.americanbankingnews.com - April 7 at 8:50 PM

SEC Filings

HTG Molecular Diagnostics (NASDAQ:HTGM) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

HTG Molecular Diagnostics (NASDAQ:HTGM) Income Statement, Balance Sheet and Cash Flow Statement

Chart

HTG Molecular Diagnostics (NASDAQ HTGM) Stock Chart for Thursday, May, 24, 2018

Loading chart…

This page was last updated on 5/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.